What is Portal?
Portal operates as a specialized cell engineering platform company, dedicated to advancing the frontiers of cellular analytics and therapeutic delivery. At its core, the company has developed a proprietary mechanical delivery system designed to facilitate the transport of diverse cargo types into a broad spectrum of cell types. This technology is engineered to be highly versatile, functioning either as a standalone solution or as an integrated component within existing laboratory and clinical workflows. By focusing on the intersection of mechanical engineering and biological research, Portal addresses the critical bottlenecks in intracellular delivery, thereby accelerating the development of advanced RNA and gene-editing therapies. The company's market position is defined by its commitment to enabling high-throughput, scalable cell engineering, which is essential for the future of personalized medicine and synthetic biology.
How much funding has Portal raised?
Portal has raised a total of $30M across 4 funding rounds:
Other Financing Round
$5M
Angel/Seed
$7M
Stock/Share Issuance
$9M
Unspecified
$9M
Other Financing Round (2024): $5M with participation from Conscience VC
Angel/Seed (2024): $7M led by Undeterred Capital, IA Ventures, Ikj Capital, Pear VC, and Page One Ventures
Stock/Share Issuance (2026): $9M, investors not publicly disclosed
Unspecified (2026): $9M featuring The NFX, Undeterred Capital, IA Ventures, Ikj Capital, Pear VC, and Techu
Key Investors in Portal
The NFX
NFX is a venture capital firm that focuses on investing in pre-seed and seed stage startups, aiming to support exceptional founders who are building transformative companies across various sectors.
Undeterred Capital
Undeterred Capital partners with founders to commercialize scientific and technological breakthroughs in biological platforms and applied robotics.
IA Ventures
IA Ventures is a venture capital firm specializing in early-stage investments in innovative technology companies, leveraging data-driven insights to guide their investment strategy.
What's next for Portal?
With the recent influx of capital, Portal is well-positioned to accelerate its commercialization efforts and expand its operational footprint. The strategic focus will likely center on deepening the integration of its delivery platform with existing biopharmaceutical pipelines, thereby solidifying its role as an essential partner in the drug discovery ecosystem. Furthermore, the company is expected to leverage its AI-driven technological capabilities to refine its delivery precision, potentially unlocking new therapeutic targets that were previously inaccessible. As Portal transitions from its foundational development phase toward broader clinical adoption, the emphasis will remain on building durable, scalable infrastructure that supports the next wave of breakthroughs in cellular therapeutics and regenerative medicine.
See full Portal company page
